CEL-SCI Reports 146 Patients Enrolled in Its Phase III Immunotherapy Head and Neck Cancer Trial

[Business Wire] – CEL-SCI Corporation today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* . more

View todays social media effects on CVM

View the latest stocks trending across Twitter. Click to view dashboard

See who Cel is hiring next, click here to view